NasdaqGS:CFMS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants.


Snowflake Analysis

Adequate balance sheet with concerning outlook.


Similar Companies

Share Price & News

How has Conformis's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CFMS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-6.7%

CFMS

0.2%

US Medical Equipment

2.5%

US Market


1 Year Return

-60.4%

CFMS

15.4%

US Medical Equipment

16.3%

US Market

Return vs Industry: CFMS underperformed the US Medical Equipment industry which returned 14.8% over the past year.

Return vs Market: CFMS underperformed the US Market which returned 15.8% over the past year.


Shareholder returns

CFMSIndustryMarket
7 Day-6.7%0.2%2.5%
30 Day-15.1%8.9%5.6%
90 Day-26.4%11.1%16.4%
1 Year-60.4%-60.4%16.4%15.4%18.8%16.3%
3 Year-80.5%-80.5%77.0%72.3%45.1%35.7%
5 Year-96.8%-96.8%120.4%103.3%75.8%56.8%

Price Volatility Vs. Market

How volatile is Conformis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Conformis undervalued compared to its fair value and its price relative to the market?

6.32x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CFMS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CFMS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CFMS is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: CFMS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CFMS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CFMS is overvalued based on its PB Ratio (6.3x) compared to the US Medical Equipment industry average (4x).


Next Steps

Future Growth

How is Conformis forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

9.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CFMS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CFMS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CFMS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CFMS's revenue (11.3% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: CFMS's revenue (11.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CFMS is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Conformis performed over the past 5 years?

13.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CFMS is currently unprofitable.

Growing Profit Margin: CFMS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CFMS is unprofitable, but has reduced losses over the past 5 years at a rate of 13.5% per year.

Accelerating Growth: Unable to compare CFMS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CFMS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.7%).


Return on Equity

High ROE: CFMS has a negative Return on Equity (-303.47%), as it is currently unprofitable.


Next Steps

Financial Health

How is Conformis's financial position?


Financial Position Analysis

Short Term Liabilities: CFMS's short term assets ($48.0M) exceed its short term liabilities ($30.1M).

Long Term Liabilities: CFMS's short term assets ($48.0M) exceed its long term liabilities ($29.1M).


Debt to Equity History and Analysis

Debt Level: CFMS's debt to equity ratio (292.1%) is considered high.

Reducing Debt: CFMS's debt to equity ratio has increased from 33.9% to 292.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CFMS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CFMS has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 24.2% each year.


Next Steps

Dividend

What is Conformis's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CFMS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CFMS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CFMS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CFMS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CFMS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Mark Augusti (54 yo)

3.75yrs

Tenure

US$2,853,754

Compensation

Mr. Mark A. Augusti has been Chief Executive Officer and President at ConforMIS, Inc. since November 14, 2016. Mr. Augusti's 27-year business career has been marked with executive management responsibility ...


CEO Compensation Analysis

Compensation vs Market: Mark's total compensation ($USD2.85M) is above average for companies of similar size in the US market ($USD598.76K).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Mark Augusti
CEO, President & Director3.75yrsUS$2.85m3.44%
$ 1.9m
J. Alldredge
Chief Legal Officer & Corporate Secretary1.08yrsUS$664.32k0.59%
$ 322.4k
Robert Howe
CFO & Treasurer0.50yrno data0.14%
$ 76.0k
Gary Maingot
Senior VP of Operations0.50yrno datano data
John Slamin
Senior Vice President of Product Engineering12.83yrsno datano data
Emmanuel Nyakako
Senior Vice President of Quality & Regulatory Affairs3.42yrsno datano data
Eric Rickenbach
Senior Vice President of US Salesno datano datano data
Erin Henry
Corporate Controller2.67yrsno data0.094%
$ 51.3k
Daniel Steines
Consultant1.83yrsUS$888.98kno data

2.3yrs

Average Tenure

50.5yo

Average Age

Experienced Management: CFMS's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mark Augusti
CEO, President & Director3.75yrsUS$2.85m3.44%
$ 1.9m
Kenneth Fallon
Independent Chairman of the Board5.5yrsUS$251.86k0.33%
$ 178.6k
Bradley Langdale
Independent Director12.25yrsUS$217.86k0.29%
$ 156.9k
Klaus Radermacher
Member of Scientific Advisory Board9.33yrsno datano data
Brian McKeon
Member of the Scientific Advisory Board11.5yrsno datano data
Thomas Thornhill
Member of Scientific Advisory Boardno datano datano data
Thomas Minas
Member of Scientific Advisory Boardno datano datano data
Wolfgang Fitz
Member of Scientific Advisory Boardno datano datano data
Richard Scott
Member of Scientific Advisory Board11.67yrsno datano data
Amar Ranawat
Member of the Scientific Advisory Board11.5yrsno datano data
Anil Ranawat
Member of the Scientific Advisory Board11.5yrsno datano data
Mahmoud Hafez
Member of Scientific Advisory Board8.92yrsno datano data

11.5yrs

Average Tenure

56yo

Average Age

Experienced Board: CFMS's board of directors are seasoned and experienced ( 11.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CFMS insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.9%.


Top Shareholders

Company Information

Conformis, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Conformis, Inc.
  • Ticker: CFMS
  • Exchange: NasdaqGS
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$54.343m
  • Shares outstanding: 77.56m
  • Website: https://www.conformis.com

Number of Employees


Location

  • Conformis, Inc.
  • 600 Technology Park Drive
  • Billerica
  • Massachusetts
  • 1821
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CFMSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2015
308DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2015

Biography

Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retai ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/07 23:39
End of Day Share Price2020/08/07 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.